DelveInsight’s “Short Bowel Syndrome Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Short Bowel Syndrome, historical and forecasted epidemiology as well as Short Bowel Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Short Bowel Syndrome Market Report
- In the 7MM, the highest prevalent cases of short bowel syndrome were seen in the United States, followed by EU4 and the UK in 2023.
- In the United States, around 29% and ~24% of short bowel syndrome cases were caused by surgical complications and mesenteric infarction respectively in 2023.
- The increase in Short Bowel Syndrome Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
- As per DelveInsight analysis, the Short Bowel Syndrome Market is anticipated to witness growth at a considerable CAGR.
- The leading Short Bowel Syndrome Companies working in the market include VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and others.
- Promising Short Bowel Syndrome Therapies in the various stages of development include Apraglutide, Glepaglutide, HM15912, and others.
- January 2024:- VectivBio AG announced a study of Phase 3 clinical trials for Apraglutide. The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF. An Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
Discover which therapies are expected to grab the Short Bowel Syndrome Market Share @ Short Bowel Syndrome Market Outlook
Short Bowel Syndrome Overview
Short bowel syndrome (SBS) is a condition that occurs when a significant portion of the small intestine is missing or non-functional. This can happen due to surgical removal of parts of the small intestine, congenital defects, or diseases that damage or remove parts of the intestine. The small intestine is responsible for absorbing nutrients from food, so when it’s shortened or damaged, it can lead to malnutrition, dehydration, and other complications. Symptoms of short bowel syndrome can include diarrhea, weight loss, malnutrition, fatigue, and electrolyte imbalances. Treatment typically involves dietary changes, medications to manage symptoms, and sometimes intravenous nutrition support.
Short Bowel Syndrome Epidemiology Insights
The epidemiology section of Short Bowel Syndrome offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Short Bowel Syndrome Epidemiology Trends @ Short Bowel Syndrome Epidemiological Insights
Short Bowel Syndrome Drugs Market
The Short Bowel Syndrome Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Short Bowel Syndrome signaling in Short Bowel Syndrome are likely to uncover new therapeutic targets and further expand treatment options for patients.
Short Bowel Syndrome Treatment Market Landscape
The Short Bowel Syndrome treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Short Bowel Syndrome has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
To learn more about Short Bowel Syndrome treatment guidelines, visit @ Short Bowel Syndrome Treatment Market Landscape
Short Bowel Syndrome Market Outlook
The report’s outlook on the Short Bowel Syndrome market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Short Bowel Syndrome therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Short Bowel Syndrome drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Short Bowel Syndrome market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.
Short Bowel Syndrome Drugs Uptake
The drug chapter of the Short Bowel Syndrome report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Short Bowel Syndrome.
Major Short Bowel Syndrome Companies
Several Short Bowel Syndrome Companies working in the market include VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and others.
Learn more about the FDA-approved drugs for Short Bowel Syndrome @ Drugs for Short Bowel Syndrome Treatment
Scope of the Short Bowel Syndrome Market Report
- Coverage- 7MM
- Short Bowel Syndrome Companies- VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and others.
- Short Bowel Syndrome Therapies- Apraglutide, Glepaglutide, HM15912, and others.
- Short Bowel Syndrome Market Dynamics: Short Bowel Syndrome Market Drivers and Barriers
- Short Bowel Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Short Bowel Syndrome Drugs in development @ Short Bowel Syndrome Clinical Trials Assessment
Table of Content
1. Key Insights
2. Report Introduction
3. Short Bowel Syndrome Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Short Bowel Syndrome Epidemiology and Market Methodology
7. Short Bowel Syndrome Disease Background and Overview
8. Short Bowel Syndrome Treatment
9. Short Bowel Syndrome Epidemiology and Patient Population
10. Short Bowel Syndrome Patient Journey
11. Short Bowel Syndrome Marketed Product
12. Short Bowel Syndrome Emerging Drugs
13. Short Bowel Syndrome: 7 Major Market Analysis
14. Short Bowel Syndrome Unmet Needs
15. Short Bowel Syndrome SWOT Analysis
16. Short Bowel Syndrome KOL Views
17. Short Bowel Syndrome Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/